Q2 EPS Estimate for Beam Therapeutics Decreased by Analyst

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Beam Therapeutics in a research note issued on Wednesday, May 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn ($1.00) per share for the quarter, down from their previous forecast of ($0.93). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.20) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q3 2026 earnings at ($1.01) EPS, Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($3.95) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($0.97) EPS, Q3 2027 earnings at ($0.91) EPS, Q4 2027 earnings at ($0.94) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($2.78) EPS, FY2029 earnings at ($2.09) EPS and FY2030 earnings at ($1.46) EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.91) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.12. Beam Therapeutics had a negative return on equity of 29.00% and a negative net margin of 39.66%.The business had revenue of $31.74 million for the quarter, compared to analyst estimates of $10.98 million. During the same period last year, the company posted ($1.23) earnings per share. Beam Therapeutics’s quarterly revenue was up 323.2% compared to the same quarter last year.

BEAM has been the topic of a number of other reports. Tudor Pickering set a $39.00 price target on shares of Beam Therapeutics in a report on Wednesday. Sanford C. Bernstein decreased their price objective on shares of Beam Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a report on Wednesday. Canaccord Genuity Group assumed coverage on shares of Beam Therapeutics in a research report on Friday, February 20th. They issued a “buy” rating and a $74.00 price objective on the stock. Wall Street Zen upgraded shares of Beam Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $46.83.

Beam Therapeutics Trading Down 7.3%

Shares of Beam Therapeutics stock opened at $29.53 on Friday. The firm has a market cap of $3.04 billion, a PE ratio of -43.43 and a beta of 2.26. Beam Therapeutics has a 1 year low of $15.35 and a 1 year high of $36.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.99 and a quick ratio of 16.99. The stock has a fifty day moving average price of $27.49 and a 200-day moving average price of $27.16.

Insider Transactions at Beam Therapeutics

In related news, insider Christine Bellon sold 5,956 shares of the business’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider directly owned 109,711 shares in the company, valued at approximately $2,696,696.38. The trade was a 5.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John M. Evans sold 30,078 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total value of $739,317.24. Following the completion of the sale, the chief executive officer owned 1,047,205 shares in the company, valued at $25,740,298.90. This represents a 2.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 79,544 shares of company stock worth $1,899,942 over the last quarter. 3.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Beam Therapeutics

Several large investors have recently modified their holdings of the business. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Beam Therapeutics in the fourth quarter valued at approximately $47,000. Hollencrest Capital Management purchased a new position in Beam Therapeutics in the 1st quarter valued at approximately $43,000. Larson Financial Group LLC grew its stake in Beam Therapeutics by 4,370.5% in the 3rd quarter. Larson Financial Group LLC now owns 1,967 shares of the company’s stock valued at $48,000 after buying an additional 1,923 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in Beam Therapeutics during the 4th quarter valued at $59,000. Finally, Van ECK Associates Corp raised its holdings in Beam Therapeutics by 48.7% during the 3rd quarter. Van ECK Associates Corp now owns 2,158 shares of the company’s stock valued at $52,000 after acquiring an additional 707 shares during the period. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics News Summary

Here are the key news stories impacting Beam Therapeutics this week:

• Positive Sentiment: Beam Therapeutics supported AlphaDetect, an initiative aimed at improving detection of alpha-1 antitrypsin deficiency, which could help broaden awareness of a genetic disease area relevant to the company’s future pipeline. Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1
• Neutral Sentiment: One commentary argued Beam is shifting from a “platform story” to a more tangible regulatory-asset story, citing its cash runway into 2029 and advancing programs in sickle cell disease and alpha-1 antitrypsin deficiency. Beam Therapeutics: Base Editing Is Moving From Platform Story To Regulatory Asset Story
• Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate for Beam Therapeutics, signaling expectations for larger losses this year than previously forecast.
• Negative Sentiment: The firm also reduced FY2027, FY2028, FY2029, and FY2030 earnings estimates, indicating a longer path to profitability than before.
• Negative Sentiment: Near-term quarterly estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027 were all lowered, suggesting continued operating losses across the development pipeline.

Beam Therapeutics Company Profile

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.